Almac to Invest in Analytical Services Capability
The API and drug product provider will invest £375,000 (US$493,000) in additional nuclear magnetic resonance (NMR) instrumentation at its headquarters in Craigavon, UK.
In a July 16, 2018 press release, contract development and manufacturing organization Almac Group announced that it will invest £375,000 (US$493,000) in additional nuclear magnetic resonance (NMR) instrumentation at its headquarters in Craigavon, UK.
Additional NMR services will be offered to support drug substance and drug product development programs from early phase to commercialization. These services include advanced characterization and purity assessment abilities in line with regulatory requirements, according to the company.
The new 500MHz NMR instrument incorporates Bruker’s Avance Neo platform and a Prodigy Cryoprobe within a temperature-controlled environment. Almac states that this setup provides greater flexibility, higher sensitivity, and resolution. The equipment also provides the capability to analyze nuclei from 15N to 31P, in addition to a range of 2D and quantitative NMR experiments, which allows the company to increase its NMR service offering, Almac reports.
Furthermore, software updates will include additional processing capabilities and improved data integrity controls to support regulatory compliance.
Source: Almac Group
